Selected article for: "high income upper middle income and upper middle income"

Author: Williams, S. R.; Driscoll, A. J.; LeBuhn, H. M.; Chen, W. H.; Neuzil, K. M.; Ortiz, J. R.
Title: National Routine Adult Immunization Programs among World Health Organization Member States: An Assessment of Health Systems to Deploy Future SARS-CoV-2 Vaccines
  • Cord-id: 59muepfx
  • Document date: 2020_10_18
  • ID: 59muepfx
    Snippet: Introduction: As the SARS-CoV-2 pandemic disproportionately affects older adults, future pandemic vaccine response will rely on existing adult immunization infrastructures. Methods: We evaluated the 2018 WHO/UNICEF Joint Reporting Form on Immunization for country reports on adult immunization programs. We described countries with programs and used multivariable regression to identify independent factors associated with having them. Results: Of 194 WHO Member States, 120 (62%) reported having any
    Document: Introduction: As the SARS-CoV-2 pandemic disproportionately affects older adults, future pandemic vaccine response will rely on existing adult immunization infrastructures. Methods: We evaluated the 2018 WHO/UNICEF Joint Reporting Form on Immunization for country reports on adult immunization programs. We described countries with programs and used multivariable regression to identify independent factors associated with having them. Results: Of 194 WHO Member States, 120 (62%) reported having any adult vaccination program. The Americas and Europe had the most adult immunization programs, most commonly Hepatitis B and influenza vaccines (>45% and >90% of countries). Africa and South-East Asia had the fewest adult immunization programs, with <11% of countries reporting any adult immunization programs for influenza or hepatitis vaccines, and none for pneumococcal vaccines. In bivariate analyses, high- or upper-middle income, introduction of new or underused vaccines, having achieved pediatric vaccine coverage goals, and meeting National Immunization Technical Advisory Groups basic functional indicators were significantly associated (p<0.001) with having any adult immunization programs. In multivariable analyses, the factor most strongly associated with adult immunization programs was country income, with high- or upper-middle income countries significantly more likely to report having a program (aOR 19.3, 95% CI 6.5, 57.7). Discussion: That 38% of countries lack functional platforms for adult immunization has major implications for future SARS-CoV-2 vaccine deployment. Systems for vaccine storage and handling, delivery, and waste management for adult immunization do not exist in much of the world. Developing countries should strengthen immunization programs to reach adults with SARS-CoV-2 vaccines when they become available.

    Search related documents:
    Co phrase search for related documents
    • absence presence and additional information: 1, 2, 3
    • absence presence and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63
    • absence presence and low income: 1, 2, 3, 4, 5, 6
    • absence presence and low middle: 1, 2, 3
    • absence presence and low middle income: 1, 2, 3
    • absence presence and low resource: 1
    • action plan and logistic regression: 1, 2, 3, 4, 5
    • action plan and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • action plan and low middle: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action plan and low middle income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action plan and low resource: 1
    • additional benefit and logistic regression: 1, 2, 3, 4, 5, 6, 7
    • additional benefit and low income: 1, 2
    • additional benefit and low middle: 1
    • additional benefit and low middle income: 1
    • additional benefit and low resource: 1
    • additional dose and logistic regression: 1, 2, 3
    • additional dose and low income: 1
    • additional dose and low middle: 1